Compare blood products and storage temperatures, revise nursing care before/during/after transfusion, and recognise acute, delayed and chronic complications with explained questions.
A transfusion gives a prescribed blood component or plasma-derived medicine through an appropriate route, usually intravenously. Component therapy replaces what is missing: red cells carry oxygen, platelets help form the initial plug, and plasma proteins/fibrinogen help form a stable clot.
Transfuse for an assessed clinical need, not a laboratory number alone. In a stable, non-bleeding adult, one red-cell unit followed by reassessment often avoids unnecessary exposure; active major haemorrhage follows a different emergency protocol.
Canadian Blood Services: Blood components · Canadian Blood Services: Transfusion reactions and premedication
| Product | What it supplies / typical use | Important distinction |
|---|---|---|
| PRBC / red-cell concentrate | Oxygen-carrying red cells for clinically important anaemia or blood loss. | Not a routine volume expander or a treatment for isolated low platelets. One unit often raises Hb about 1 g/dL in a non-bleeding adult; response varies. |
| Platelets: random-donor, pooled or apheresis | Prevention/treatment of bleeding caused by low platelets or platelet dysfunction, according to the cause and procedure. | An apheresis adult dose is not equivalent to one small random-donor unit. Do not automatically transfuse in TTP/HIT; seek specialist advice, particularly unless life-threatening bleeding. |
| FFP | Multiple coagulation factors for appropriate bleeding/coagulopathy, major haemorrhage or selected plasma-exchange indications. | Not nutritional support, routine volume replacement, or treatment of every mildly abnormal INR. |
| Cryoprecipitate | Concentrated fibrinogen, with factors VIII/XIII and von Willebrand factor; mainly used for bleeding with low/dysfunctional fibrinogen. | Not interchangeable with platelets. Specific factor concentrates are preferred for many inherited factor deficiencies when available. |
| Whole blood | Red cells plus plasma; selected major-haemorrhage protocols may use appropriately selected whole blood. | Not automatically preferable for routine anaemia; stored whole blood is not equivalent to a fresh functional platelet dose. |
| Granulocytes | Specialist-selected treatment for severe neutropenia with serious infection when appropriate. | Rare, specially ordered cellular component; compatibility, irradiation and rapid-use requirements are managed by the blood centre. |
| Albumin | Fractionated plasma protein used for selected clinical indications. | Does not replace red cells or the complete coagulation-factor mixture. Concentration and infusion instructions matter. |
| IV immunoglobulin, factor concentrates and PCC | Manufactured products for specific immune or coagulation disorders; PCC may be used for urgent warfarin reversal with vitamin K when indicated. | Brand-specific reconstitution, rate, storage and adverse effects apply. They are not ordinary FFP. |
Canadian Blood Services: Blood components · Lifeblood: Use of platelets · New Zealand Blood Service: Plasma components and indications
| Modification | Main purpose | What it does not guarantee |
|---|---|---|
| Leucoreduced / leucodepleted | Reduces white-cell content, helping reduce selected febrile and alloimmune risks. | Does not replace irradiation when protection against TA-GVHD is required. |
| Irradiated cellular components | Inactivates donor lymphocytes to prevent TA-GVHD in at-risk recipients. | Does not mean sterile; does not replace compatibility testing. Check the revised expiry. |
| Washed red cells | Removes much of the residual plasma/protein; useful in selected patients with severe/recurrent allergic reactions. | Not routinely needed for all recipients. Processing can change expiry and availability. |
| Antigen-negative / phenotype-matched | Avoids relevant red-cell antigens in patients with antibodies or selected chronic-transfusion needs. | A historical antibody still matters even if a current screen no longer detects it. |
Lifeblood: Red cells and modified products · Lifeblood: Transfusion-associated graft-versus-host disease · Lifeblood: Delayed haemolytic transfusion reactions
| Component | Controlled storage | Revision point |
|---|---|---|
| Whole blood / PRBC | 2–6°C in a validated blood-bank refrigerator. | CPD whole blood: up to 21 days; CPDA-1: up to 35 days. Red cells with approved additive solution may last up to 42 days. Read the pack label. |
| Conventional platelets | 20–24°C, with continuous gentle agitation during storage. | Indian standards describe 3–5 days depending on the bag/system. Some services validate longer storage; never infer expiry from temperature alone. |
| Frozen FFP | −30°C or colder in the cited Indian standard. | Up to 1 year under that standard. Controlled thawing is performed by trained blood-centre staff; follow the issued expiry. |
| Frozen cryoprecipitate | −30°C or colder in the cited Indian standard. | Up to 1 year frozen. After thawing, generally use within 6 hours under that standard; pooling/opening may alter limits. |
| Thawed plasma | Blood-centre-controlled conditions and labelled expiry; not returned to routine frozen stock. | Prompt use is important. Indian standards distinguish early coagulation-factor use and refrigerated storage up to 24 hours for specified uses. Do not choose an extension at the bedside. |
| Granulocytes | Typically 20–24°C; specialist short-expiry supply. | Transfuse as soon as possible under the blood-centre instructions; not routine refrigerator storage. |
| Albumin / IVIG / concentrates | Manufacturer-specific. | Some products permit room-temperature storage; others require refrigeration. Never assume every blood product is stored at 2–8°C. |
Why textbooks differ: Lifeblood, for example, specifies frozen components at ≤−25°C and conventional platelets up to 7 days in its validated system. Those figures should not be silently substituted for the cited Indian standard.
MoHFW: National Standards for Blood Centres, component storage and administration · Lifeblood: Storage and handling
For red cells, donor red-cell antigens must be compatible with the recipient. For plasma, donor plasma antibodies must not attack the recipient’s red cells. O-negative red cells are not “universal” plasma or whole blood. Emergency release is a blood-bank/medical decision; change to appropriate matched components when directed.
| Recipient ABO group | Compatible donor red-cell ABO groups | Compatible donor plasma ABO groups |
|---|---|---|
| O | O | O, A, B or AB |
| A | A or O | A or AB |
| B | B or O | B or AB |
| AB | AB, A, B or O | AB |
ABO-identical components are generally preferred when feasible. RhD, antibodies, crossmatch results and special requirements are additional checks. RhD-negative patients—especially girls/women with future pregnancy potential—need careful selection; a blood bank may advise anti-D after selected RhD-positive platelet exposures. Do not select components from a memorised table without the laboratory’s issue label.
Canadian Blood Services: Blood administration · Canadian Blood Services: Transfusion reactions and premedication · Lifeblood: Red cells and modified products
Lifeblood: Monitoring and observation · Canadian Blood Services: Blood administration · MoHFW: National Standards for Blood Centres, component storage and administration · Lifeblood: Equipment, medicines and IV-fluid compatibility
Canadian Blood Services: Blood administration · Lifeblood: Monitoring and observation · Lifeblood: Delayed haemolytic transfusion reactions
Restart rule: never independently restart. A clinician may allow cautious resumption after a genuinely mild isolated allergic/febrile event has settled, serious causes have been excluded, and the product is still valid. Suspected haemolysis, sepsis, anaphylaxis, TACO or TRALI: do not restart the implicated unit.
Acute reactions usually occur during transfusion or within 24 hours, but each diagnosis has its own definition and time window. The table is a recognition guide, not a substitute for urgent assessment.
| Reaction / mechanism | Clinical clues and timing | Focused management after STOP + ABCs |
|---|---|---|
| Acute haemolytic reaction | Often minutes after incompatible red cells: fever/rigors, back or chest pain, hypotension, dark urine; may progress to kidney injury, DIC and shock. | Urgent blood-bank/medical review; recheck identity. Support perfusion/urine output and investigate haemolysis, compatibility and coagulopathy. Do not give another unit without specialist direction. |
| Febrile non-haemolytic reaction (FNHTR) | Fever, often with chills during/soon after transfusion; immune/inflammatory response. | A diagnosis of exclusion. Exclude haemolysis and bacterial contamination before calling it “just fever”; prescribed antipyretic may be used after assessment. |
| Mild allergic reaction | Isolated hives/itch without respiratory/circulatory involvement, often related to plasma proteins. | Observe for progression. An antihistamine may relieve skin symptoms. Reassessment and authorisation are required before any restart. |
| Anaphylaxis | Rapid airway swelling, wheeze/stridor, hypotension/collapse; a rash may be absent. | Emergency IM adrenaline, airway/oxygen support and prescribed IV fluid; do not wait for antihistamines or steroids. Seek specialist advice about future products. |
| Bacterial contamination / septic reaction | High fever, severe rigors, hypotension, tachycardia, vomiting or collapse; platelets are particularly vulnerable to bacterial growth. | Take patient cultures and send pack/set for culture; prompt IV antibiotics and sepsis care. The blood service may need to quarantine associated components. |
| TACO | Volume/pressure overload during or up to 12 hours: dyspnoea, pulmonary oedema, often hypertension, raised JVP and positive fluid balance. | Oxygen, upright positioning when appropriate, pause other fluids and prescribed diuretic/support. Review risk, dose and rate before future transfusions. |
| TRALI | Noncardiogenic lung injury during or within 6 hours: hypoxaemia and bilateral infiltrates, often fever/hypotension without clear overload. | Oxygen/ventilatory and haemodynamic support; notify blood bank. Diuretics are not routine treatment and can worsen hypotension. |
| Hypotensive reaction / other causes | A marked BP fall may have multiple explanations, including anaphylaxis, sepsis, haemolysis or a hypotensive transfusion reaction. | Urgently exclude serious causes and review medicines/other illness; do not diagnose from BP alone. |
| Rapid/massive-transfusion complications | Citrate-related hypocalcaemia, potassium disturbance, hypothermia and dilutional/consumptive coagulopathy. | Use the major-haemorrhage protocol; monitor ionised calcium, potassium, temperature, gases and clotting. Replace what is indicated, with frequent reassessment. |
Lifeblood: Management of suspected transfusion reactions · Lifeblood: Transfusion-associated circulatory overload · Lifeblood: Transfusion-related acute lung injury · Canadian Blood Services: Transfusion reactions and premedication
| Feature | TACO | TRALI |
|---|---|---|
| Main problem | Hydrostatic / circulatory overload | Increased lung permeability / acute lung injury |
| Typical window | During or within 12 hours | During or within 6 hours |
| Helpful clues | Positive balance, raised JVP; hypertension common; cardiac/renal risk | No clear overload; hypotension/fever may occur |
| Tests to support assessment | CXR, fluid balance, BNP/NT-proBNP and echo as indicated | CXR and clinical exclusion of alternative causes; specialised donor/recipient testing when advised |
| Treatment direction | Oxygen, fluid adjustment and prescribed diuretic | Respiratory/circulatory support; not routine diuresis |
Both can cause severe hypoxaemia and both need immediate action. They can overlap with each other or another condition; BNP, CXR or BP alone does not settle the diagnosis.
Lifeblood: Transfusion-associated circulatory overload · Lifeblood: Transfusion-related acute lung injury
| Complication / mechanism | When and what to look for | Investigation / prevention / care |
|---|---|---|
| Delayed haemolytic reaction (DHTR) | Usually 24 hours–28 days after red cells: poor Hb rise or later Hb fall, jaundice, low fever and haemolysis; an old antibody may have become undetectable before re-exposure. | CBC/Hb, bilirubin, LDH, haptoglobin, DAT and repeat antibody testing. Notify the blood bank; record antibodies and obtain appropriate antigen-negative units if further transfusion is necessary. Severe haemolysis requires urgent specialist care. |
| Alloimmunisation / platelet refractoriness | Antibodies to red-cell or HLA/HPA antigens can complicate future transfusion; a poor platelet increment may also be caused by sepsis, bleeding, DIC or splenic sequestration. | Review timed post-transfusion counts and nonimmune causes, then specialised antibody testing/matched products when indicated. Do not assume every low increment is immune. |
| Post-transfusion purpura (PTP) | Often 7–10 days later: sudden severe thrombocytopenia, bruising or mucosal bleeding due to platelet-antigen antibodies. | Urgent haematology review, platelet count and antibody work-up; IVIG is a specialist treatment. Bleeding needs an individual emergency plan. |
| TA-GVHD | Often around 1–2 weeks: fever, rash, diarrhoea, liver abnormalities and pancytopenia as donor T cells attack recipient tissues. Often fatal. | Urgent specialist investigation, sometimes biopsy/chimerism studies. Prevention with appropriate irradiated cellular components is crucial; leucoreduction alone is not an equivalent substitute. |
| Transfusional iron overload | Months/years of repeated red-cell exposure can load liver, heart and endocrine organs; fatigue, hepatic dysfunction, cardiomyopathy and endocrine problems may develop. | Trend transfusion burden/ferritin and organ assessment; MRI liver iron/cardiac T2* when indicated. Specialist chelation removes excess iron. Ferritin can also rise with inflammation. |
| Transfusion-transmitted infection | Symptoms may be delayed according to the organism’s incubation period. Donor screening lowers risk but does not make it zero. | Investigate according to symptoms/exposure, notify the blood service and follow haemovigilance/trace-back procedures. Timing and treatment are organism-specific. |
Lifeblood: Delayed haemolytic transfusion reactions · Canadian Blood Services: Transfusion reactions and premedication · Lifeblood: Post-transfusion purpura · Lifeblood: Transfusion-associated graft-versus-host disease · Lifeblood: Transfusional iron overload
| Drug / treatment | Appropriate role | Nursing consideration |
|---|---|---|
| 0.9% sodium chloride | Compatible line fluid and prescribed resuscitation support. | For a suspected reaction, use a fresh setup; do not flush residual implicated blood. Titrate fluids to the clinical problem—large volumes can worsen overload. |
| Adrenaline / epinephrine | First-line for anaphylaxis. Standard IM dose: 0.01 mg/kg of 1 mg/mL, maximum 0.5 mg; an adult >50 kg usually receives 0.5 mg = 0.5 mL IM into the anterolateral thigh. Repeat after 5 minutes if needed under the emergency protocol. | Read the concentration and route aloud. This is not the 1-mg IV/IO cardiac-arrest dose. Do not give a routine IV bolus of 1 mg/mL adrenaline for anaphylaxis. |
| Antihistamine | Relief of isolated allergic skin symptoms, or a selected recurrence plan. | Not a replacement for adrenaline in airway/breathing/circulatory anaphylaxis; monitor sedation and BP. |
| Paracetamol / acetaminophen | Prescribed treatment of fever once serious transfusion causes are assessed. | Do not suppress fever and continue transfusion without investigation; consider liver disease and total dose. |
| Furosemide / other prescribed diuretic | Treatment of TACO; sometimes prevention in a selected high-risk patient. | Assess BP, electrolytes, urine output and fluid balance. Not automatic for every unit and not routine for TRALI. |
| Broad-spectrum IV antibiotics | Suspected bacterial contamination/sepsis. | Obtain ordered cultures promptly without materially delaying urgent antibiotics; do not discard the pack. |
| Calcium replacement | Clinically important/monitored citrate-related hypocalcaemia, especially during major haemorrhage. | Dose, formulation and route are prescribed; monitor ionised calcium/ECG. Never mix calcium into the blood bag or unverified blood line. |
| IVIG | Specialist treatment for PTP and selected other immune problems. | Brand-specific rate, reaction, renal and thrombosis precautions apply. |
| Iron chelators | Deferasirox, deferiprone or desferrioxamine for selected transfusion-dependent patients with iron overload. | Long-term specialist treatment, not an acute-reaction antidote. Follow drug-specific renal, liver or blood-count monitoring; urgently report fever if neutropenia is a concern. |
Canadian Blood Services: Transfusion reactions and premedication · Australian Immunisation Handbook: IM adrenaline for anaphylaxis · ASCIA: Acute management of anaphylaxis, updated 2026 · Lifeblood: Management of suspected transfusion reactions · UCLH NHS: Iron chelation medicines
| When | Tests / assessment | Reason |
|---|---|---|
| Before transfusion | CBC/Hb/platelets; ABO/RhD and antibody screen; red-cell compatibility testing; review previous antibodies and special product requirements. | Confirm need and prevent incompatibility. Emergency-release procedures are authorised exceptions, not bedside shortcuts. |
| Before plasma/cryo or major haemorrhage | PT/INR, aPTT, fibrinogen; other tests guided by bleeding and illness. | Select the component and assess the deficit rather than treating one result without context. |
| After an uncomplicated transfusion | Repeat Hb, platelet count or coagulation/fibrinogen when ordered; assess clinical response and fluid balance. | Check whether the intended benefit occurred. A falling Hb may reflect bleeding or haemolysis, not just “insufficient blood”. |
| Suspected haemolysis | Repeat identity/group/compatibility, DAT and antibody screen; Hb/CBC, bilirubin, LDH, haptoglobin, renal function, potassium and urine assessment. | Identify incompatibility and organ injury; add DIC tests if severe. |
| Fever with shock / possible sepsis | Patient blood cultures and appropriate cultures/assessment of the component and set through the laboratory. | Identify bacterial contamination and guide treatment; associated components may need quarantine. |
| Respiratory reaction | SpO₂/gas exchange, CXR, fluid balance; BNP/echo for possible overload; targeted TRALI work-up after specialist assessment. | Differentiate TACO, TRALI, anaphylaxis and other causes, without waiting to support breathing. |
| Repeated transfusions / delayed symptoms | Antibody history, Hb/platelet trends, ferritin and indicated iron MRI; targeted infection, PTP or TA-GVHD tests. | Prevent missed late reactions and monitor cumulative harm. |
Canadian Blood Services: Blood administration · Lifeblood: Management of suspected transfusion reactions · Lifeblood: Transfusional iron overload · Lifeblood: Delayed haemolytic transfusion reactions
Choose one best answer, then reveal the explanation. These are original practice questions for nursing students.
Correct answer: B. Packed red cells
Rationale: Red cells carry haemoglobin. The other products treat different deficiencies and do not substitute for red-cell oxygen transport.
Correct answer: D. Return it promptly to the blood service for approved 20–24°C storage with agitation
Rationale: Conventional platelets are not routinely refrigerated like PRBC. The blood service maintains the validated temperature and handling conditions.
Correct answer: A. Cryoprecipitate
Rationale: Cryoprecipitate replaces fibrinogen. Component selection still depends on the bleeding protocol, measured deficit and available concentrates.
Correct answer: C. Do not start; resolve the discrepancy with the blood bank
Rationale: A discrepancy is a stop point. Identity errors can cause fatal incompatible transfusion; neither a similar name nor bed location is enough.
Correct answer: A. Stop the transfusion and activate urgent assessment
Rationale: This may be haemolysis or sepsis. Stop exposure, assess ABCs and summon help rather than assuming a benign fever.
Correct answer: C. TACO
Rationale: The combination suggests hydrostatic overload. Assessment must still exclude or identify overlapping causes of respiratory distress.
Correct answer: B. Stop transfusion and provide respiratory/circulatory support
Rationale: TRALI causes acute lung injury. Oxygen/ventilatory support is central; routine diuresis is not appropriate for a non-overload process.
Correct answer: D. IM adrenaline according to the emergency protocol
Rationale: Anaphylaxis threatens the airway and circulation. Antihistamines/steroids do not replace prompt adrenaline.
Correct answer: C. Routine PRBC require a validated 2–6°C blood refrigerator
Rationale: Conventional red cells and platelets have different validated storage conditions. A ward food fridge is not a blood refrigerator.
MoHFW: National Standards for Blood Centres, component storage and administration
Correct answer: A. −30°C or colder
Rationale: The cited Indian standard uses −30°C or colder. Other countries may specify different validated frozen-storage limits.
MoHFW: National Standards for Blood Centres, component storage and administration
Correct answer: D. Haemolysis tests, DAT and repeat antibody/compatibility assessment
Rationale: A delayed haemolytic reaction can appear after discharge. The blood bank needs the history and laboratory evidence to select safer future blood.
Correct answer: B. Premedication is individualised; routine use is not reliably preventive
Rationale: Routine premedication has limited supporting evidence. Correct checks and monitoring remain essential with or without medicines.
Canadian Blood Services: Transfusion reactions and premedication
Correct answer: C. Clarify and obtain the prescribed preparation; leucoreduction does not replace irradiation
Rationale: Irradiation targets viable donor lymphocytes to prevent TA-GVHD. Leucoreduction has a different purpose.
Correct answer: D. Iron chelation with specialist monitoring
Rationale: Repeated red cells add iron that can injure organs. Chelation removes accumulated iron; it is not an acute transfusion-reaction treatment.
Correct answer: A. Use a separate compatible route/setup as directed; do not mix calcium into the blood
Rationale: Calcium-containing solutions can cause clotting when mixed with citrated blood. Replacement must use the prescribed compatible administration plan.
Correct answer: B. The treating clinician under the reaction policy after reassessment and exclusion of serious causes
Rationale: Mild isolated events sometimes permit cautious resumption, but only after authorised reassessment and confirmation that the product remains valid.
Sources checked 23 October 2026. Indian storage figures are explicitly labelled; international sources support clinical comparisons and nursing practice. Actual component preparation, shelf life, issue limits and reaction procedures follow the licensed label, local blood centre and current hospital protocol. This is adult-focused nursing education; neonatal/paediatric dose, rate and component requirements need a specific prescription. Independent specialist review is not claimed.
Nursing Medium